Medtronic Stock Buy or Sell? MDT Stocks Forecast

Market Capitalization: 108 070 019 000 $
EBITDA: 8 633 000 000 $
Price to Earnings: 26.72
Quarterly Earnings Growth YOY: -0.165
Quarterly Revenue Growth YOY: -0.005
Trailing PE: 26.72
Forward PE: 14.88
Shares Outstanding: 1330420000

Medtronic Stock Buy or Sell? MDT Stocks Analytic Forecasts

March 23, 2023 (22:50)

Medtronic plc. (MDT) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the MDT stock market. Experts share their opinions on what to expect from the Medtronic plc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Medtronic stocks.

Medtronic plc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy MDT Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Hoya Capital and is titled

“Medtronic: A Smart Dividend Gem To Buy On The Cheap”

is published on March 10 (2023) and has 8 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Medtronic is seeing a decent rebound to its topline, as the healthcare segment recovers.
  • Management is transforming the company through cost reductions and investments in high growth and synergistic areas.
  • The stock pays a decent dividend and appears to be value priced at present.

The author starts his analytic review with the following:

Higher interest rates have caused plenty of indigestion for the market, as reflected by performance over the past few weeks.

This author is very popular among the auditory. He has 32493 followers

Hoya Capital is the contributor of experts community since 2015 and has a great number of published articles – 1996.

One more noteworthy article is written by Canadian Dividend Growth Investor under the title

“Medtronic: Slow Growth Makes Me Hesitate To Buy”

on March 10 (2023) and has 2 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add MDT stocks to your investment portfolio or not, and helps to work out your own Medtronic stock selling strategies:

  • Medtronic seems to be a blue-chip company that’s committed to increasing its dividend.
  • Its financial position is stable, and its payout ratio is sustainable.
  • Its ~3.5% yield and A-grade credit rating suggest its a relatively low-risk stock investment.
  • Slow EPS growth has been weighing on the stock.

Canadian Dividend Growth Investor starts analysis with such words:

The stock of Ireland-based Medtronic (NYSE:MDT) has been in a slump for the past 1.5 years – down close to 37% in that period.

The opinion of the author can be considered quite authoritative.
The number of 6887 followers confirms this.
Canadian Dividend Growth Investor is the contributor of experts community since 2012. Has already published at least 237 articles.

Another analysis presented by Geoff Considine came out on March 9 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for MDT stocks. It sounds like

“Medtronic Struggling To Grow Earnings”

Article has got 1 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Medtronic plc., the expert says the following:

  • Medtronic has experienced several setbacks in addition to COVID-related headwinds.
  • The earnings outlook is weak.
  • The Wall Street consensus view on MDT has been too positive over the last several years.
  • The market-implied outlook (calculated from options prices) is slightly bullish, with moderate volatility.

And here, what comes first:

Medtronic (NYSE:MDT) is the largest medical device company in the world, with 90,000 employees in 150 countries and $31.7 Billion in revenues in 2022. After recovering steadily from the COVID-driven share decline in early 2020 to September of 2021, the stock currently trades at about 41% below the all-time high closing price of $135.17 on September 8, 2021. Medtronic has suffered some setbacks in recent years, in addition to the impacts of COVID. In late 2021, the company received a warning letter from the FDA about quality control in production of insulin delivery devices. In late 2022, trials of a treatment for hypertension, RDN, failed to perform satisfactorily. The rollout of Medtronic’s surgical robot, Hugo, has experienced delays. The company has been hampered by supply chain constraints in its medical surgery business. At the current price, the shares are not far above the levels during the worst of the COVID drawdown in early 2020. Management is implementing restructuring and cost cutting to help the company in weathering this difficult period.

The opinion of the author can be considered quite authoritative.
The number of 5793 followers confirms this.
Geoff Considine is the contributor of experts community since 2006. Has already 472 analytic reviews published.

The Share Price of Medtronic plc. (MDT) for now

What analysts predict: $92.09
52-week high/low: $111.55 / $75.1

50/200 Day Moving Average: $81.96 / $85.03

The average stock price over the previous 50/200 days. For Medtronic stocks, the 50-day moving average is the resistance level for now. For MDT stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for MDT stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

What Pfizer Is Getting From The Seagen Acquisition

Buy or Sell PFE shares? What Pfizer Is Getting From The Seagen Acquisition
March 13, 2023
Pfizer will acquire Seagen for $43 billion or $229 per share.

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Buy or Sell LLY shares? Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 23, 2023
84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.